注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
此成分基金的目标是借投资于由在医疗行业作为创新先锋的生物医药公司所发行的股票或类似证券,以达致增长。成分基金将至少以其净资产的三分之二投资于由从事该行业的公司所发行的股票。此成分基金的投资并没有地域上的限制,但由于医药行业所有创新产品集中于北美及西欧,此成分基金的大部分投资亦集中于这些地区。为了就医药行业的创新项目提供资金,此生物科技成分基金最多可以其净资产的10%投资于私人股票及/或非上市证券。
名称 | 标题 | 任期 | 至 |
---|---|---|---|
Eugénio Martin-Fougeroux | - | 2023 | now |
Marco Minonne | Vice President | 2020 | now |
背景介紹 | Marco Minonne, CFA, Senior Vice President, rejoined the firm in 2013. Marco is part of the Growth Equity Group which is responsible for Neuberger Berman’s Mid Cap Growth and Small Cap Growth strategies. He is an Associate Portfolio Manager on Small Cap Growth and a Research Analyst covering the health care sector on Mid Cap Growth. Prior to rejoining Neuberger Berman, Marco was a senior therapeutic analyst with Columbia Management. He has previously held research analyst positions at Citadel Investment Group, Neuberger Berman and Northern Trust Bank. Marco has extensive buy-side experience in health care and has been involved in both long-only and long-short strategies. Marco earned a Bachelor of Arts in Finance and Economics from the University of Iowa and has been awarded the Chartered Financial Analyst designation. | ||
Tazio Storni | - | 2016 | now |
Lydia Haueter | - | 2016 | now |
Grégoire Biollaz | - | 2016 | 2017 |
Nathalie Flury | - | 2016 | 2017 |
Michael Sjöström | - | 1995 | 2016 |
Carmen Tang | - | 2008 | 2012 |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核